Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23 2024 - 6:00PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, and its collaborators will share data from
seven studies at the 2024 ASCO Annual Meeting. Three studies led by
Myriad focus on breast cancer risk assessment, and four additional
studies will be shared by collaborators that will cover the
company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic
Test, and the Myriad Collaborative Research Registry™ (MCRR). At
booth 25014, Myriad will highlight the value of genetic testing and
genomic insights in guiding personalized cancer treatment
decisions, as well as share information about upcoming product
innovations including MRD and liquid biopsy testing.
New Data at ASCO
Oral Presentation: Evaluation of a polygenic
risk score as a predictor of early onset triple-negative breast
cancer in Black women (Abstract #: 10501)
Presenter: Holly J. Pederson, MD, Director,
Medical Breast Services, Cleveland ClinicDate:
Saturday, June 1, 2024Time: 3:12 pm
CTDescription: This study demonstrates that
Myriad’s RiskScore improves upon clinical factors for the
prediction of triple-negative breast cancer and early onset (<50
years) triple-negative breast cancer in Black women.
Poster: Comparison of primary versus metastatic
tumor tissue sources when designing panels for whole-genome-based
tumor-informed ctDNA assays in clear cell renal cell carcinoma
(Abstract #3039)Date: Saturday, June 1,
2024Time: 9:00am – 12:00pm
CTDescription: In a pilot study of patients with
oligometastatic renal cell carcinoma, molecular residual disease
(MRD) results were largely concordant with mortality status and
between monitoring panels composed of thousands of probes
identified from either primary or metastatic tumors, suggesting
repeat biopsy might not be necessary for long term MRD
monitoring.
Poster: Improving a polygenic risk score (PRS)
for breast cancer (BC) risk assessment in diverse
ancestries (Abstract #: 10533)Date: Monday,
June 3, 2024Time: 1:30 – 4:30pm
CTDescription: This study highlights a new 385-SNP
PRS component of RiskScore and demonstrates it is well-calibrated,
improves upon clinical factors, and outperformed existing PRS in
all tested ancestries for the prediction of breast cancer risk.
Poster: Association of polygenic-based breast
cancer risk prediction with patient management (Abstract #:
10527) Date: Monday, June 3,
2024Time: 1:30 – 4:30pm
CTDescription: The study demonstrates that
clinicians recommended breast cancer screening aligned with
guidelines for those with ≥20% lifetime risk, regardless of whether
risk was based on RiskScore or on Tyrer-Cuzick
alone.
Poster: Germline Genetic Profiles of Women with
Ovarian Malignancies: A Myriad Collaborative Research Registry
Study (Abstract #: 5585)Date: Monday, June 3,
2024Time: 9:00 am – 12:00pm
CTDescription: This data shows that over 15% of
patients with ovarian cancer have BRCA1/2 (12.5%) or Lynch syndrome
(2.6%) pathogenetic variants varying by race, age, and tumor site.
Noted disparities indicate the importance of universal testing in
patients with ovarian cancer.
Poster: Germline Genetic Profiles of Women with
Uterine Cancer: A Myriad Collaborative Research Registry
Study (Abstract #: 5617)Date: Monday, June 3,
2024Time: 9:00 am – 12:00pm
CTDescription: There are significant differences
in germline testing results for women with uterine cancer by race,
ethnicity, and age, especially in genes associated with Lynch
syndrome. This has implications for immunotherapy eligibility in
the advanced and recurrent setting. More work needs to be done to
identify targetable mutations in minority populations.
Poster: Neoadjuvant combination treatment of
olaparib and pembrolizumab for patients with HRD-positive advanced
ovarian cancer (Abstract #: 5545)Date: Monday,
June 3, 2024Time: 9:00 am – 12:00pm
CTDescription: This study shows that neoadjuvant
combination therapy of olaparib and pembrolizumab is effective and
tolerable in patients with HRD-positive advanced ovarian cancer.
BRCA1/2 mutations are associated with the efficacy of combination
therapy.
Myriad Oncology InnovationsMyriad continues to
expand its oncology portfolio and expertise through product
innovations and the addition of new team members, including the
appointment of George Daneker Jr., MD, who is the president and
chief clinical officer of oncology. Myriad’s Precise™ Oncology
Solutions portfolio features comprehensive germline and somatic
testing options, including the MyRisk® Hereditary Cancer Test with
RiskScore®, Precise™ Tumor Test, Prolaris® Prostate Cancer
Prognostic Test, EndoPredict® Breast Cancer Prognostic Test, Folate
Receptor Alpha (Frα) Test, and Myriad’s two FDA-approved companion
diagnostic tests: MyChoice CDx HRD Companion Diagnostic Test and
BRACAnalysis CDx® Germline Companion Diagnostic Test.
Ongoing oncology developments include:
- MRD testing. Myriad’s Precise MRD is a
tumor-informed, whole genome sequencing (WGS) based test that
monitors hundreds to thousands of tumor-specific variants. This
technology enables exceptional sensitivity and quantification of
circulating tumor DNA (ctDNA) in the blood of patients with cancer.
The test is currently available for use in research studies pursued
jointly by Myriad and academic or pharmaceutical investigators and
is expected to launch commercially in 2025.MRD research
collaborations. In the past year, Myriad has announced
several important research collaborations: a retrospective study of
MRD efficacy in metastatic breast cancer with researchers at
Memorial Sloan Kettering Cancer Center (MSK), a retrospective
analysis of MRD utility in metastatic renal cell carcinoma with
clinicians at The University of Texas MD Anderson Cancer Center,
and a prospective pan-cancer study with MRD researchers at the
National Cancer Center Hospital East in Japan. Early results from
the research collaboration with MD Anderson will be shared at ASCO
as a poster.
- Tumor profiling and liquid biopsy testing.
Earlier this year, Myriad acquired select assets from Intermountain
Precision Genomics’ laboratory business. By bringing Precise Tumor
and Precise Liquid testing in house at Myriad's new
state-of-the-art laboratory facility in Salt Lake City, the company
opens new opportunities to scale and develop its portfolio. Precise
Liquid is expected to launch in 2025.
- Expanding data sharing efforts. Launched in
December 2023, the MCRR includes data across germline and tumor
testing results from Myriad’s cancer products on more than one
million patients, making it one of the largest pan-cancer
registries freely available for research use and supports
transparent clinical data sharing. Two of the above posters being
shared at ASCO are based on data from the MCRR. Myriad is also
expanding its collaboration with its technology partner DNAnexus to
provide a new, interactive way for physicians to securely access
their data, with more details to come later this year.
“As we continue to innovate and grow our oncology business, our
vision remains centered around advancing oncology care for all
patients,” said Dr. Daneker. “Our new research and product
innovations underscore our commitment to partnering with
oncologists, academic institutions and other healthcare partners to
expand access to genetic and genomic testing, create equitable
testing solutions for all, and provide data-driven insights that
can better inform clinical care and improve outcomes for
patients.”
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the data and information that the company
plans to present at the 2024 ASCO Annual Meeting and updates on
upcoming product innovations including MRD and liquid biopsy
testing. These “forward-looking statements” are management’s
expectations of future events as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially and
adversely from those anticipated. Such factors include those risks
described in the company’s filings with the U.S. Securities and
Exchange Commission, including the company’s Annual Report on Form
10-K filed on February 28, 2024, as well as any updates to those
risk factors filed from time to time in the company’s Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not
under any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024